

Serum amyloid A level in preeclampsia

Thesis

Submitted for Partial Fulfillment of Master Degree
in **Obstetrics & Gynecology**

Presented by

Mohamed Ahmed El-Sayed El-Nems

M.B.B.Ch

Ain Shams University (2009)

Supervised by

Prof. Dr. Mohamed Adel El-Nazer

Professor of Obstetrics and Gynecology

Faculty of Medicine - Ain Shams University

Dr. Ahmed Hussieny Salama

Lecturer of Obstetrics and Gynecology

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain Shams University

2013

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٢٢



To Allah goes **My deepest gratitude** and thanks for achieving any work in my life.

I would like to express my deepest gratitude to **Prof. Dr. Mohamed Adel El-Nazer**, Professor of Obstetrics and Gynecology, Ain Shams University for dedicating so much of his precious time and effort to help me complete this work. I really appreciate so much his constant guidance and assistance to me.

Indeed, words do fail me when I come to express my unlimited appreciation to **Dr. Ahmed Hussieny Salama**, Lecturer of Obstetrics and Gynecology, Ain Shams University who was always there to help me, to encourage me and very kindly offer me his valuable remarks in every step of this work.

I can't forget **Assistant Prof. Dr./ Mostafa Ibrahim** the one who has chosen this interesting subject.

Finally, I am so grateful to **all members of My family** for providing me with great support and I'm most thankful to **My Father** the one who enlightened the path for me.

Contents

Subjects	Page
• List of abbreviations	I
• List of Tables	III
• List of figures	IV
• Introduction	1
• Aim of the work.....	4
• Review of literature:	
- Preeclampsia	5
- Serum Amyloid A	38
- New Biochemical markers.....	59
• Methodology.....	79
• Results.....	84
• Discussion.....	98
• Summary & Conclusion.....	107
• References.....	109
• Arabic summary	

List of Abbreviations

ACOG	: American College of Obstetricians and Gynecologists
ADAM12	: A disintegrin and metalloprotease 12
BP	: Blood pressure
CBC	: Complete blood count
CK	: Creatine kinase
CNS	: Central nervous system
CTG	: Cardiotocograph
CVP	: Central venous pressure
DBP	: Diastolic blood pressure
DIC	: Disseminated intravascular coagulopathy
ELISA	: Enzyme linked immunosorbent assays
FDA	: Food and drug administration
Flt	: Fms-like tyrosine kinase
HDL	: High density lipoprotein
HLA	: Human Leukocyte antigen
IUGR	: Intrauterine growth restriction
LCAT	: Lecithin cholesterol acyltransferase
LDL	: Low density lipoprotein
NK	: Natural killer
PIGF	: Placental growth factor.

.....
List of Abbreviations
.....

PP-13	: Placental protein 13
PTX3	: Pentraxin3
RIA	: Radioimmuno assays
SAA	: Serum amyloid A
SBP	: Systolic blood pressure
SD	: Standard deviation
sEng	: Soluble endoglin
TNF	: Tumor necrosis factor
VEGF	: Vascular endothelial growth factor
VLDL	: Very low density lipoprotein

List of Tables

Table No.	Title	Page
Table (1):	Patients' characteristics	84
Table (2):	Comparison between the 2 study groups	85
Table (3):	Serum amyloid A level correlations among the whole study sample	87
Table (4):	Group 1 characteristics	89
Table (5):	Serum amyloid A level correlations among group 1 (cases)	90
Table (6):	Comparison between patients with SAA of ≥ 0.8 and patients with SAA of < 0.8 .	93
Table (7):	Univariate logistic regression analysis	94
Table (8):	Comparison between patients with adverse outcome (maternal and/or neonatal morbidity and mortality) and patients with no adverse outcome	95

List of Figures

Figure No.	Title	Page
Figure (1):	Sequential proposed steps in SAA's physiological function mobilizing and recycling macrophage cholesterol. Most of the relevant references are cited in the text.	49
Figure (2):	Bar diagram showing mean and 95% CI of serum amyloid A in both study groups.	85
Figure (3):	Box-and-whisker plot showing median serum amyloid A (horizontal bar inside boxes) and its distribution among the 2 study groups (p=0.00).	86
Figure (4):	Scatter plot showing the correlation between serum amyloid A and gestational age among the whole study sample (p=0.005).	87
Figure (5):	Scatter plot showing the correlation between serum amyloid A and BMI among the whole study sample (p=0.005).	88
Figure (6):	Scatter plot showing the correlation between serum amyloid A and BMI among group 1 (p=0.018).	91
Figure (7):	ROC curve showing the impact of serum amyloid A level on maternal morbidity (area under the curve=0.76, p=0.003). A cut off value for SAA of 0.8 had sensitivity of 58.3% and specificity of 100%.	91

Figure No.	Title	Page
Figure (8):	ROC curve showing the impact of serum amyloid A level on neonatal morbidity/mortality (area under the curve=0.773, p=0.001). A cut off value for SAA of 0.8 had sensitivity of 63.6% and specificity of 100%.	92
Figure (9):	ROC curve showing the impact of serum amyloid A level on combined maternal and/or neonatal morbidity/mortality (area under the curve=0.8, p=0.0001). A cut off value for SAA of 0.8 had sensitivity of 66.6% and specificity of 100%.	92
Figure (10):	Serum amyloid A (mean, 95% CI) among patients with and without adverse outcome (any maternal or neonatal morbidity/mortality).	96
Figure (11):	Box-and-whisker plot showing median and distribution of serum amyloid A levels (horizontal bar inside boxes=median) among patients with and without adverse outcome (any maternal or neonatal morbidity/mortality), p=0.009.	97

Introduction

Hypertensive disorders with pregnancy are one of the main reasons of maternal, fetal and neonatal morbidity and mortality. As preeclampsia is a multisystem disorder with different clinical characteristics, prevention, early management of this disease requires a close interdisciplinary cooperation^[1].

It affects about 5-10% of all pregnancies and is a major cause of maternal, fetal and neonatal mortality and morbidity³ as amniotic fluid levels, decreased fetal growth, placental abruption, and intrauterine fetal demise^[2].

The etiology of preeclampsia is unknown but thought to be related to placental hypoxia^[3]. Many theories have attempted to explain why preeclampsia arises, and have linked the syndrome to the presence of the following:

- Endothelial cell injury.
- Immune rejection of the placenta.
- Compromised placental perfusion.
- Altered vascular reactivity.
- Imbalance between prostacyclin and thromboxane.
- Decreased glomerular filtration rate with retention of salt and water.
- Decreased intravascular volume.
- Increased central nervous system irritability^[4]

Preeclampsia is a syndrome, which affects virtually all-maternal organ systems^[5], it is a multisystem disorder and lead to a lot of cellular death and endothelial injury.

Dysfunction of endothelial cells can contribute to inappropriate vasoconstriction and platelet aggregation which are early signs of atherosclerosis, hypertension and coronary vasospasm^[6].

Serum amyloid A (SAA) is one of the acute phase proteins predominantly produced and secreted by hepatocytes. Other cells including lymphocytes, monocytes, and macrophages can also produce this protein.

The induction of SAA synthesis is triggered by a number of cytokines, chiefly IL-6 and TNF- predominantly released from macrophages and monocytes at the inflammatory sites^[7]. The synthesis is influenced by steroid hormones and adipose tissue (due to IL-6 production in the adipocytes)^[8,9]. Increased baseline level of SAA analyzed by high-sensitivity assays has been recognized as markers of vascular wall inflammation and as clinical marker for the prediction of cardiovascular events^[10].

Since preeclampsia is associated with widespread endothelial dysfunction, proposed to be provoked by an increased maternal systemic inflammatory response, the

maternal plasma levels of SAA might be expected to be increased when compared to normal pregnancy levels.

The maternal plasma levels of SAA in normal pregnancy could differ from non-pregnant levels due to increased hormone levels, increased adipose tissue and/or secondary to modifications of the inflammatory response in normal pregnancy^[11].

Aim of the work

The aim of this study is to correlate plasma levels of serum amyloid A protein in pregnant women with preeclampsia in order to get a new biochemical marker for preeclampsia and explore possible correlation with maternal and neonatal morbidity & mortality.

Preeclampsia

Overview

Preeclampsia is a disorder of widespread vascular endothelial malfunction and vasospasm that occurs after 20 weeks' gestation and can present as late as 4-6 weeks postpartum. It is clinically defined by hypertension and proteinuria, with or without pathologic edema.

In developing nations, the incidence of the disease is reported to be 4-18%,^[12, 13] with hypertensive disorders being the second most common obstetric cause of stillbirths and early neonatal deaths in these countries.^[14]

Medical consensus is lacking regarding the values that define preeclampsia, but reasonable criteria in a woman who was normotensive before 20 weeks' gestation include a systolic blood pressure (SBP) greater than 140 mm Hg and a diastolic BP (DBP) greater than 90 mm Hg on 2 successive measurements, 4-6 hours apart. Preeclampsia in a patient with preexisting essential hypertension is diagnosed if SBP has increased by 30 mm Hg or if DBP has increased by 15 mm Hg.

Classification and Characteristics of Hypertensive Disorders

Preeclampsia is part of a spectrum of hypertensive disorders that complicate pregnancy, the classification is as follows^[15]:

- Gestational hypertension
- Chronic hypertension
- Preeclampsia/eclampsia
- Superimposed preeclampsia (on chronic hypertension)

Although each of these disorders can appear in isolation, they are thought of as progressive manifestations of a single process and are believed to share a common etiology.

Gestational hypertension

The characteristics of gestational hypertension are as follows:

- BP of 140/90 mm Hg or greater for the first time during pregnancy.
- No proteinuria.
- BP returns to normal less than 12 weeks' postpartum.
- Final diagnosis made only postpartum.